{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:06:39Z","timestamp":1766088399504,"version":"3.41.0"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.2169\/internalmedicine.4488-24","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T22:10:59Z","timestamp":1733350259000},"page":"2019-2023","source":"Crossref","is-referenced-by-count":2,"title":["Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib"],"prefix":"10.2169","volume":"64","author":[{"given":"Naohiro","family":"Oda","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reo","family":"Mitani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Tokura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"doi-asserted-by":"crossref","unstructured":"1. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383: 931-943, 2020.","key":"1","DOI":"10.1056\/NEJMoa2004407"},{"doi-asserted-by":"crossref","unstructured":"2. Sakai H, Morise M, Kato T, et al. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. Jpn J Clin Oncol 51: 1261-1268, 2021.","key":"2","DOI":"10.1093\/jjco\/hyab072"},{"doi-asserted-by":"crossref","unstructured":"3. Vanhoutte T, Sprangers B. Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker. Clin Kidney J 16: 603-610, 2023.","key":"3","DOI":"10.1093\/ckj\/sfad011"},{"doi-asserted-by":"crossref","unstructured":"4. Wijtvliet V, Roosens L, De Bondt C, Janssens A, Abramowicz D. Pseudo-acute kidney injury secondary to tepotinib. Clin Kidney J 16: 760-761, 2023.","key":"4","DOI":"10.1093\/ckj\/sfac180"},{"doi-asserted-by":"crossref","unstructured":"5. Chen MF, Harada G, Liu D, et al. Brief report: tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to "false" decreases in renal function. J Thorac Oncol 19: 153-159, 2024.","key":"5","DOI":"10.1016\/j.jtho.2023.09.1444"},{"unstructured":"6. U.S. Food and Drug Administration. Drug label for TEPMETKO. Published 2021 [Internet]. [cited 2024 Jun 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214096s000lbl.pdf","key":"6"},{"doi-asserted-by":"crossref","unstructured":"7. Mohan A, Herrmann SM. Capmatinib-induced pseudo-acute kidney injury: a case report. Am J Kidney Dis 79: 120-124, 2022.","key":"7","DOI":"10.1053\/j.ajkd.2021.04.009"},{"doi-asserted-by":"crossref","unstructured":"8. Yokoyama S, Nakagawa J, Aiuchi N, Seito T, Niioka T. Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprim-sulfamethoxazole without changes in glomerular filtration rate. J Clin Pharm Ther 47: 1409-1417, 2022.","key":"8","DOI":"10.1111\/jcpt.13679"},{"doi-asserted-by":"crossref","unstructured":"9. Hack SP, Bruey J-M, Koeppen H. HGF\/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 5: 2866-2880, 2014.","key":"9","DOI":"10.18632\/oncotarget.2003"},{"doi-asserted-by":"crossref","unstructured":"10. Usui J, Yamagata K, Imai E, et al. Clinical practice guideline for drug-induced kidney injury in Japan 2016: digest version. Clin Exp Nephrol 20: 827-831, 2016.","key":"10","DOI":"10.1007\/s10157-016-1334-0"},{"doi-asserted-by":"crossref","unstructured":"11. Le X, Sakai H, Felip E, et al. Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin Cancer Res 28: 1117-1126, 2022.","key":"11","DOI":"10.1158\/1078-0432.CCR-21-2733"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/13\/64_4488-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:46:07Z","timestamp":1751687167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/13\/64_4488-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":11,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4488-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"4488-24"}}